Skip Navigation LinksHome > September 2008 - Volume 107 - Issue 3 > Respiratory Depression After Neuraxial Opioids in the Obstet...
Anesthesia & Analgesia:
doi: 10.1213/ane.0b013e318168b443
Obstetric Anesthesiology: Review Article

Respiratory Depression After Neuraxial Opioids in the Obstetric Setting

Carvalho, Brendan MBBCh, FRCA

Free Access
Continued Medical Education
Chinese Language Editions
Article Outline
Collapse Box

Author Information

From the Department of Anesthesia, Stanford University School of Medicine, Stanford, California.

Accepted for publication December 28, 2007.

The author received no internal or external funding for the preparation of this review. Dr. Carvalho’s work is supported by a Building Interdisciplinary Careers in Women’s Health Research grant from the Office of Research on Women’s Health and National Institute of Child Health and Human Development of the National Institutes of Health (5K12 HD043452).

Conflict of Interest: The author has previously received funding from SkyePharma, Inc., San Diego, CA and Endo Pharmaceuticals, Chadds Ford, PA for conducting cesarean delivery analgesia studies using extended-release epidural morphine (DepoDur™).

Reprints will not be available from the author.

Address correspondence to Brendan Carvalho, MBBCh, FRCA, Department of Anesthesia, H3580, Stanford University School of Medicine, Stanford, CA 94305. Address e-mail to bcarvalho@stanford.edu.

Collapse Box

Abstract

Neuraxial opioids have contributed significantly to improved labor and postcesarean delivery analgesia. In the obstetric population, epidural and intrathecal opioids are associated with a very low risk of clinically significant respiratory depression. Although rare, respiratory depression is a serious risk; patients may die or suffer permanent brain damage as a consequence. This review discusses the mechanism and incidence, as well as the prevention, detection, and management of respiratory depression with morphine, extended-release epidural morphine, and lipophilic opioids in the labor and cesarean delivery setting.

Pain associated with delivery is the most important anesthetic-related concern for expectant mothers.1 Compared with systemic opioids or regional techniques that use local anesthetics alone, neuraxial opioids provide superior labor and postcesarean analgesia.2–4 Most cesarean deliveries are performed with spinal or epidural anesthesia5; 60%–70% of women in the United States receive neuraxial analgesia during labor.6,7 Although rare, respiratory depression is a potentially serious risk after epidural and intrathecal opioid administration. Recent closed-claim data report 16 cases of respiratory depression involving neuraxial opioids, with 73% of these patients dying or suffering permanent brain damage.8 This review discusses the mechanism and incidence, as well as the prevention, detection, and management of respiratory depression after neuraxial opioid administration in the obstetric setting.

Back to Top | Article Outline

MECHANISM AND PHARMACOKINETICS

Neuraxial opioids depress the respiratory centers in the brainstem via direct and/or indirect mechanisms, as shown in Table 1.9–15 Respiratory depression after neuraxial morphine is biphasic16: it can occur early (30–90 min) after epidural administration of hydrophilic morphine due to systemic vascular absorption,10 or it can occur late (6–18 h) after epidural or intrathecal morphine due to rostral spread in cerebrospinal fluid and slow penetration into the brainstem.17 In contrast, lipophilic opioids (e.g., fentanyl and sufentanil) do not cause delayed respiratory depression, but they may cause early-onset respiratory depression, typically within 30 min due to significant vascular uptake, rostral spread via cerebrospinal fluid, and potentially by direct transit in epidural veins.9,12

Table 1
Table 1
Image Tools
Back to Top | Article Outline

INCIDENCE

Nonobstetric studies report an incidence of respiratory depression after neuraxial opioids of 0.01%–7%.18,19 Retrospective, observational studies may under-estimate the true incidence. Also, the fact that there is no standard definition of respiratory depression20 may contribute to misestimating the incidence. Respiratory rate, hypercarbia, low Spo2, sedation, depressed ventilatory response to hypoxia or hypercarbia, and naloxone treatment have all been used as indicators of respiratory depression.20

Back to Top | Article Outline

MORPHINE SULFATE

Cesarean Delivery

Morphine is currently the “gold-standard” neuraxial opioid for postcesarean analgesia. It provides effective postoperative analgesia for 12–24 h.21 The incidence of respiratory depression after neuraxial morphine administration ranges from 0% to 0.9% (Table 2).22–26 No studies reported serious sequelae, although some patients required naloxone administration.22,23

Table 2
Table 2
Image Tools

Early reports suggested that intrathecal morphine was more likely to cause delayed respiratory depression than epidural morphine.10 However, this fact likely reflected the higher intrathecal morphine doses (1–5 mg) reported in early clinical studies.27 More recently, smaller doses of intrathecal morphine have been found to provide effective analgesia with a low risk of respiratory depression. In one study, neither 0.1 nor 0.25 mg intrathecal morphine affected minute ventilation or the ventilatory responses to CO2, whereas both measurements were depressed for 3 h after 8 mg subcutaneous morphine.28

Back to Top | Article Outline
Labor Analgesia

In isolation, the efficacy of intrathecal (0.5–2 mg) or epidural (up to 7.5 mg) morphine for labor analgesia is limited by a long latency (15–60 min), incomplete analgesia, and maternal side effects.29–32 In combination with lipophilic opioids and local anesthetic, intrathecal morphine in small doses (0.1–0.3 mg) may prolong or improve labor and postpartum analgesia.33–38 However, side effects (e.g., nausea, vomiting, and pruritus) and concerns for respiratory depression limit neuraxial morphine’s role in a labor setting.39,40 In community hospitals with limited anesthesia services, neuraxial morphine for labor analgesia is still occasionally used.41 The incidence of respiratory depression in a community practice was reported as 1.3%,33 but it is likely that respiratory depression is under-reported in this setting. Although a case of postpartum respiratory depression was reported 7 h after 1 mg intrathecal morphine administration in labor,42 investigators in several studies using smaller intrathecal doses (0.1–0.5 mg) did not report respiratory depression.34–37

Back to Top | Article Outline

EXTENDED-RELEASE EPIDURAL MORPHINE (EREM)

Single-dose epidural or intrathecal morphine provides effective analgesia for 12–24 h postcesarean,21 shifting peak pain levels to the second postoperative day.43 EREM (DepoDur™) delivers standard morphine via multi-vesicular lipid, sustained-release, drug-delivery technology.44–46 A single, 10-mg dose of EREM compared with standard epidural morphine 4–5 mg significantly reduced opioid consumption and pain for 48 h postcesarean delivery without significant respiratory depression in this young, healthy population.47,48 However, small sample sizes used in these studies do not allow the respiratory depression incidence to be accurately calculated. Respiratory depression has been reported with larger EREM doses (15–30 mg) administered for hip and knee arthroplasty and lower abdominal surgery.49–51 The dose-related incidence of respiratory depression ranged from 2% to 16%, with 8% to 21% of patients requiring naloxone to reverse opioid-related adverse events.49–52 Compared with obstetric patients, the surgical patients were higher risk, older, and many received general anesthesia. In the obstetric setting, cautious use of EREM is prudent in high-risk patients (e.g., those with obesity or obstructive sleep apnea, or those who receive magnesium).

Back to Top | Article Outline

LIPOPHILIC OPIOIDS

Labor Analgesia

Lipophilic drugs alone or in combination with bupivacaine are used as a single-dose spinal, part of a combined-spinal epidural technique, and/or combined with epidural local anesthetic solutions to improve analgesia, reduce local anesthetic use and decrease motor block. Respiratory depression after administration of lipophilic opioids in a labor setting is very rare. A few case reports describe respiratory depression or arrest after intrathecal sufentanil 10–15 μg,53–59 fentanyl 10 μg (after 100 μg of epidural fentanyl),60 and meperidine 50 mg.59 Cases typically occur within 4–20 min after intrathecal dosing, and respiratory depression was often associated with prior systemic opioid administration and repeated neuraxial doses. A retrospective analysis of 4870 patients who received intrathecal sufentanil 10 μg for labor analgesia found the risk of respiratory depression was 0.02% (1 of 4870, 95% CI: 0%–0.06%).55 Evidence from nonpregnant patients suggests that plasma levels of fentanyl (and, to a lesser extent, of sufentanil) increase progressively during continuous epidural administration and may decrease ventilatory response to CO2 and increase Paco2.61,62 However, despite widespread use of epidural opioids in modern obstetric practice, this author is unaware of reports of significant respiratory depression in this setting. In one retrospective study, no patients (0 in 10,047, 95% CI: 0%–0.03%) who received continuous labor epidural infusions containing bupivacaine with 1.45 μg/mL fentanyl had respiratory depression.55

Back to Top | Article Outline
Cesarean Delivery

Neuraxially administered lipophilic opioids (e.g., fentanyl 10–15 μg) improve intraoperative analgesia and reduce nausea and vomiting during cesarean delivery.63 The incidence of clinically significant respiratory depression after lipophilic drugs in the cesarean delivery setting is unknown, but probably very low. In one case, respiratory depression requiring naloxone reversal occurred 25 min after spinal anesthesia that included intrathecal fentanyl 15 μg.64 Epidural fentanyl 100 μg or sufentanil 10–50 μg added to lidocaine for cesarean delivery caused statistically significant changes of respiratory rate and end-tidal CO2.65 In another study, intrathecal fentanyl 20 μg added to bupivacaine for cesarean delivery improved the quality of neuraxial blockade, but it did not cause deterioration in peak expiratory flow rate or vital capacity.66 Respiratory depression has been described after epidural fentanyl 90–100 μg for cesarean delivery.67,68 Epidural sufentanil (30–50 μg) depressed ventilatory response to CO2 after cesarean delivery, although overt respiratory depression did not occur.12

Back to Top | Article Outline

PREVENTION

Identify Patients at Risk

Respiratory depression risk factors in the nonobstetric setting include advanced age, morbid obesity, cardiopulmonary disease, obstructive sleep apnea, and preoperative opioid tolerance.18 Although obesity is common, obstetric patients are relatively young and healthy. They rarely present with significant pulmonary disease or other risk factors for respiratory depression. Pregnant women also have increased progesterone, a respiratory stimulant that may further decrease the risk of respiratory depression. However, because opioid-induced respiratory depression occasionally occurs in healthy patients without comorbidity who receive standard doses of neuraxial opioid,8 we must expect this rare, but hazardous event in our obstetric population.8,69

In morbidly obese patients, increased surveillance after administering neuraxial morphine is necessary. In one study of 856 patients, all 8 who experienced respiratory depression after intrathecal morphine for cesarean delivery were markedly obese.26 Before neuraxial opioids are administered, a history and physical directed at identifying sleep apnea and coexisting disease should be performed. Because hypermagnesemia can cause respiratory depression, extra vigilance is needed with preeclamptic women receiving magnesium sulfate for seizure prophylaxis. Caution should be exercised when any other opioids or sedative drugs (e.g., diphenhydramine) are administered because they may increase the risk of respiratory depression.8 Multiple order sets prescribing parenteral or oral opioids to treat breakthrough pain pose a particular hazard to patients who have received neuraxial opioids.

Back to Top | Article Outline
Limit Opioid Dose and Distribution

In the past, large opioid doses were common and the respiratory depression incidence was more frequent. In the obstetric setting, neuraxial morphine has an analgesic efficacy ceiling.70,71 Large neuraxial opioid doses increase side effects without significant prolongation of analgesia. For cesarean delivery, intrathecal doses of morphine >100–200 μg21,70 and epidural doses >2–4 mg71 are unnecessary. There is a similar analgesic ceiling with lipophilic opioids in labor; doses >2.5–7.5 μg sufentanil or >10–25 μg fentanyl may increase the risk of respiratory depression and other side effects without significantly improving analgesia.72–75 Although respiratory depression risk is dose-related and larger doses (intrathecal sufentanil ≥10 μg or fentanyl ≥50 μg) are more likely to cause respiratory depression, small doses can also cause respiratory depression.60,76

Plain bupivacaine and opioid mixtures (e.g., sufentanil and fentanyl) are hypobaric.77 Rostral spread of lipophilic opioids may be minimized by limiting the duration spent in the sitting position after block placement.78 Hyperbaric local anesthetic solutions may decrease rostral spread of the opioid, but provide inferior labor analgesia compared with plain (hypobaric) solutions.79

Back to Top | Article Outline

MONITORING, DETECTION, AND TREATMENT

Use Appropriate Methods of Respiratory Monitoring

A recent closed-claim analysis estimated that 56% of respiratory events after neuraxial opioids could have been prevented.8 The American Society of Anesthesiologists (ASA) approved guidelines in 2007 that address respiratory depression associated with neuraxial opioid administration.18 These guidelines are scheduled to be revised in 2008. However, these general guidelines do not specifically address obstetric patients in labor or postcesarean delivery.

Opioid effects on respiration include decreased minute ventilation (decreased respiratory rate, tidal volume or both), decreased response to hypoxia, and a rightward shift and depression of the CO2 response.80,81 All patients receiving neuraxial opioids should be monitored for adequacy of ventilation, oxygenation, and level of consciousness. Unfortunately, current monitoring technology and clinical observation practices are unreliable and yield both false positives and negatives.8 Intermittent evaluation of clinical signs (respiratory rate, level of sedation, pupil size) are often unreliable predictors of respiratory depression. The respiratory rate of patients with sleep apnea may be misleading, as there may be chest-wall movement without ventilation due to airway obstruction.8 Pulse oximetry, a noninvasive monitor of oxygenation, has poor sensitivity to detect hypoventilation and hypercarbia, especially when supplemental oxygen is administered. Increased surveillance is warranted in patients at high risk of respiratory depression who are receiving oxygen. Brief episodes of desaturation are common 24 h postcesarean delivery. In one study, 71% of patients had ≥1 episode of oxyhemoglobin saturations <85% after epidural morphine 5 mg administration for cesarean delivery.82 Continuous pulse oximetry is inconvenient and impractical for the postpartum patient due to frequent motion-artifact alarms and lack of central monitoring on most postpartum units. Similarly, apnea monitors, associated with frequent, annoying false alarms, do not detect hypoventilation. End-tidal Pco2 monitoring in unintubated patients has significant limitations, and it is not yet universally available.

There are spare outcome data to guide the selection and frequency of respiratory monitoring. Routine continuous pulse oximetry (while appropriate for the obstetric patient with risk factors such as obesity) may be unnecessary in healthy postcesarean patients when small doses of opioids (e.g., intrathecal morphine ≤0.2 mg, epidural morphine ≤4 mg) are used. Although intermittent respiratory monitoring may miss transient episodes of desaturation and bradypnea, respiratory depression typically progresses slowly, often preceded by increasing maternal sedation. Regular assessments (e.g., hourly) and vigilant nursing observations of respiratory effort, respiratory rate, or unusual somnolence are probably adequate in low-risk obstetric patients.22,83–85 Nursing staff should be adequately trained in detecting and treating opioid-induced respiratory depression, and an anesthesia care provider should be readily available to manage complications that may arise.

Back to Top | Article Outline
Monitor Respiration for an Appropriate Duration

CO2 responsiveness was depressed for up to 24 h postcesarean delivery after administration of 5 mg epidural morphine.86 Thus, it is prudent to continue respiratory monitoring for about 24 h after administering neuraxial morphine. The recently approved ASA guidelines recommend that respiratory monitoring after single-dose neuraxial morphine should occur at least every hour for the first 12 h, then every 2 h for the next 12 h. Patients receiving continuous infusions of neuraxial opioids should be monitored for the duration of the infusion. Because of the potential risk of delayed respiratory depression beyond 24 h, the ASA Task Force recommends that patients receiving epidural EREM should be monitored for up to 48 h.18 Prolonged monitoring currently recommended for EREM18,83 may be overly conservative, as respiratory depression beyond 24 h with single-dose EREM in doses ≤10 mg has not been reported.48,52

Early-onset respiratory depression associated with lipophilic opioids usually occurs within 30 min of administration and is likely to occur in a high-visibility, controlled setting (e.g., operating or labor room). The ASA Task Force recommends that after neuraxial administration of lipophilic opioids (e.g., fentanyl), continual respiratory monitoring should be performed for a minimum of 2 h after administration or discontinuation of the infusion. These recommendations are not specific to the obstetric setting and may be overly conservative and impractical to implement in a busy labor suite after discontinuation of an epidural infusion. However, continuous respiratory monitoring for 2–4 h after bolus doses of lipophilic opioids for cesarean delivery should be performed. Investigators reported respiratory depression 100 min after 100 μg epidural fentanyl for cesarean delivery.67 In another study of ventilatory changes after 200 μg of epidural fentanyl, investigators found that it took 180 min to return to baseline.9

Back to Top | Article Outline
Treat Respiratory Depression

Physicians and nursing staff must be educated to prevent, recognize, and treat respiratory depression. Treatment protocols and mechanisms to ensure a rapid response to respiratory events should be in place. Patients who display altered level of consciousness, bradypnea, or hypoxemia require treatment and more intensive monitoring until symptoms have resolved. Although supplemental oxygen should be available, its routine use is not recommended, because it may increase the duration of apnea and reduce the sensitivity of pulse oximetry for detecting hypoventilation.8 Naloxone is indicated in patients with more than transient somnolence and respiratory depression that does not respond to arousal. If naloxone fails to reverse severe respiratory depression or arrest, prompt mask ventilation and/or endotracheal intubation should be performed. An intravenous infusion of naloxone (2–10 mg over 24 h) should be maintained for as long as the patient remains symptomatic.87–90 The routine administration of prophylactic naloxone is not recommended.85 Patients already using continuous positive airway pressure devices should continue to do so postpartum.

Back to Top | Article Outline

IN SUMMARY

Neuraxial opioids have contributed to improved analgesia during labor and after cesarean delivery. The analgesic benefits derived from neuraxial opioids far outweigh the risks of a rare respiratory depression event; a risk that is not significantly increased with neuraxial compared with parenteral opioid administration. In the obstetric population, although neuraxial opioids are associated with a very low risk of clinically significant respiratory depression, it does occur, and may have fatal consequences.8 If we identify patients at risk and adequately monitor their ventilation, oxygenation, and level of consciousness, we will be able to decrease the risk of adverse outcomes. Despite the rarity of respiratory depression in the obstetric population, we must be prepared to diagnose and treat this potentially deadly complication.

Back to Top | Article Outline

REFERENCES

1. Carvalho B, Cohen SE, Lipman SS, Fuller A, Mathusamy AD, Macario A. Patient preferences for anesthesia outcomes associated with cesarean delivery. Anesth Analg 2005;101:1182–7

2. Wu CL, Cohen SR, Richman JM, Rowlingson AJ, Courpas GE, Cheung K, Lin EE, Liu SS. Efficacy of postoperative patient-controlled and continuous infusion epidural analgesia versus intravenous patient-controlled analgesia with opioids: a meta-analysis. Anesthesiology 2005;103:1079–88

3. Cohen SE, Subak LL, Brose WG, Halpern J. Analgesia after cesarean delivery: patient evaluations and costs of five opioid techniques. Reg Anesth 1991;16:141–9

4. Lim Y, Jha S, Sia AT, Rawal N. Morphine for post-caesarean section analgesia: intrathecal, epidural or intravenous? Singapore Med J 2005;46:392–6

5. Jenkins JG, Khan MM. Anaesthesia for caesarean section: a survey in a UK region from 1992 to 2002. Anaesthesia 2003;58:1114–18

6. Bucklin BA, Hawkins JL, Anderson JR, Ullrich FA. Obstetric anesthesia workforce survey: twenty-year update. Anesthesiology 2005;103:645–53

7. Carvalho B, Wang P, Cohen SE. A survey of labor patient-controlled epidural anesthesia practice in California hospitals. Int J Obstet Anesth 2006;15:217–22

8. Weinger M. Dangers of postoperative opioids. APSF Newsletter 2007;21:61–8

9. Negre I, Gueneron JP, Ecoffey C, Penon C, Gross JB, Levron JC, Samii K. Ventilatory response to carbon dioxide after intramuscular and epidural fentanyl. Anesth Analg 1987;66:707–10

10. Cousins MJ, Mather LE. Intrathecal and epidural administration of opioids. Anesthesiology 1984;61:276–310

11. Gourlay GK, Cherry DA, Plummer JL, Armstrong PJ, Cousins MJ. The influence of drug polarity on the absorption of opioid drugs into CSF and subsequent cephalad migration following lumbar epidural administration: application to morphine and pethidine. Pain 1987;31:297–305

12. Cohen SE, Labaille T, Benhamou D, Levron JC. Respiratory effects of epidural sufentanil after cesarean section. Anesth Analg 1992;74:677–82

13. Bernards CM. Recent insights into the pharmacokinetics of spinal opioids and the relevance to opioid selection. Curr Opin Anaesthesiol 2004;17:441–7

14. Bernards CM, Shen DD, Sterling ES, Adkins JE, Risler L, Phillips B, Ummenhofer W. Epidural, cerebrospinal fluid, and plasma pharmacokinetics of epidural opioids (part 1): differences among opioids. Anesthesiology 2003;99:455–65

15. Gourlay GK, Murphy TM, Plummer JL, Kowalski SR, Cherry DA, Cousins MJ. Pharmacokinetics of fentanyl in lumbar and cervical CSF following lumbar epidural and intravenous administration. Pain 1989;38:253–9

16. Kafer ER, Brown JT, Scott D, Findlay JW, Butz RF, Teeple E, Ghia JN. Biphasic depression of ventilatory responses to CO2 following epidural morphine. Anesthesiology 1983;58:418–27

17. Bromage PR, Camporesi EM, Durant PA, Nielsen CH. Rostral spread of epidural morphine. Anesthesiology 1982;56:431–6

18. Horlocker TS. Practice Guidelines for the Prevention, Detection and Management of Respiratory Depression Associated with Neuraxial Opioid Administration: Preliminary Report by ASA Task Force on Neuraxial Anesthesia. ASA Newsletter 2007;71:24–6

19. Shapiro A, Zohar E, Zaslansky R, Hoppenstein D, Shabat S, Fredman B. The frequency and timing of respiratory depression in 1524 postoperative patients treated with systemic or neuraxial morphine. J Clin Anesth 2005;17:537–42

20. Ko S, Goldstein DH, VanDenKerkhof EG. Definitions of “respiratory depression” with intrathecal morphine postoperative analgesia: a review of the literature. Can J Anaesth 2003;50:679–88

21. Dahl JB, Jeppesen IS, Jorgensen H, Wetterslev J, Moiniche S. Intraoperative and postoperative analgesic efficacy and adverse effects of intrathecal opioids in patients undergoing cesarean section with spinal anesthesia: a qualitative and quantitative systematic review of randomized controlled trials. Anesthesiology 1999;91:1919–27

22. Fuller JG, McMorland GH, Douglas MJ, Palmer L. Epidural morphine for analgesia after caesarean section: a report of 4880 patients. Can J Anaesth 1990;37:636–40

23. Leicht CH, Hughes SC, Dailey PA, Schnider SM, Rosen MA. Epidural morphine sulfate for analgesia after cesarean section: a prospective report of 1000 patients. Anesthesiology 1986;65:A366

24. Kotelko DM, Dailey PA, Shnider SM, Rosen MA, Hughes SC, Brizgys RV. Epidural morphine analgesia after cesarean delivery. Obstet Gynecol 1984;63:409–13

25. McMorland GH, Douglas MJ. Epidural morphine for postoperative analgesia. Can Anaesth Soc J 1986;33:115–16

26. Abouleish E, Rawal N, Rashad MN. The addition of 0.2 mg subarachnoid morphine to hyperbaric bupivacaine for cesarean delivery: a prospective study of 856 cases. Reg Anesth 1991;16:137–40

27. Etches RC, Sandler AN, Daley MD. Respiratory depression and spinal opioids. Can J Anaesth 1989;36:165–85

28. Abboud TK, Dror A, Mosaad P, Zhu J, Mantilla M, Swart F, Gangolly J, Silao P, Makar A, Moore J, et al. Mini-dose intrathecal morphine for the relief of post-cesarean section pain: safety, efficacy, and ventilatory responses to carbon dioxide. Anesth Analg 1988;67:137–43

29. Scott PV, Bowen FE, Cartwright P, Rao BC, Deeley D, Wotherspoon HG, Sumrein IM. Intrathecal morphine as sole analgesic during labour. BMJ 1980;281:351–5

30. Baraka A, Noueihid R, Hajj S. Intrathecal injection of morphine for obstetric analgesia. Anesthesiology 1981;54:136–40

31. Hughes SC, Rosen MA, Shnider SM, Abboud TK, Stefani SJ, Norton M. Maternal and neonatal effects of epidural morphine for labor and delivery. Anesth Analg 1984;63:319–24

32. Abboud TK, Shnider SM, Dailey PA, Raya JA, Sarkis F, Grobler NM, Sadri S, Khoo SS, DeSousa B, Baysinger CL, et al. Intrathecal administration of hyperbaric morphine for the relief of pain in labour. Br J Anaesth 1984;56:1351–60

33. Herpolsheimer A, Schretenthaler J. The use of intrapartum intrathecal narcotic analgesia in a community-based hospital. Obstet Gynecol 1994;84:931–6

34. Vasudevan A, Snowman CE, Sundar S, Sarge TW, Hess PE. Intrathecal morphine reduces breakthrough pain during labour epidural analgesia. Br J Anaesth 2007;98:241–5

35. Hess PE, Vasudevan A, Snowman C, Pratt SD. Small dose bupivacaine-fentanyl spinal analgesia combined with morphine for labor. Anesth Analg 2003;97:247–52

36. Yeh HM, Chen LK, Shyu MK, Lin CJ, Sun WZ, Wang MJ, Mok MS, Tsai SK. The addition of morphine prolongs fentanyl-bupivacaine spinal analgesia for the relief of labor pain. Anesth Analg 2001;92:665–8

37. Wu JL, Hsu MS, Hsu TC, Chen LH, Yang WJ, Tsai YC. The efficacy of intrathecal coadministration of morphine and bupivacaine for labor analgesia. Acta Anaesthesiol Sin 1997;35:209–16

38. Goodman SR, Drachenberg AM, Johnson SA, Negron MA, Kim-Lo SH, Smiley RM. Decreased postpartum use of oral pain medication after a single dose of epidural morphine. Reg Anesth Pain Med 2005;30:134–9

39. Grieco WM, Norris MC, Leighton BL, Arkoosh VA, Huffnagle HJ, Honet JE, Costello D. Intrathecal sufentanil labor analgesia: the effects of adding morphine or epinephrine. Anesth Analg 1993;77:1149–54

40. Caldwell LE, Rosen MA, Shnider SM. Subarachnoid morphine and fentanyl for labor analgesia. Efficacy and adverse effects. Reg Anesth 1994;19:2–8

41. Rust LA, Waring RW, Hall GL, Nelson EI. Intrathecal narcotics for obstetric analgesia in a community hospital. Am J Obstet Gynecol 170:1643–6, 1994; discussion 6–8

42. Abouleish E. Apnoea associated with the intrathecal administration of morphine in obstetrics. A case report. Br J Anaesth 1988;60:592–4

43. Angle PJ, Halpern SH, Leighton BL, Szalai JP, Gnanendran K, Kronberg JE. A randomized controlled trial examining the effect of naproxen on analgesia during the second day after cesarean delivery. Anesth Analg 2002;95:741–5

44. Howell SB. Clinical applications of a novel sustained-release injectable drug delivery system: DepoFoam technology. Cancer J 2001;7:219–27

45. Angst MS, Drover DR. Pharmacology of drugs formulated with DepoFoam: a sustained release drug delivery system for parenteral administration using multivesicular liposome technology. Clin Pharmacokinet 2006;45:1153–76

46. Mantripragada S. A lipid based depot (DepoFoam technology) for sustained release drug delivery. Prog Lipid Res 2002;41:392–406

47. Carvalho B, Riley E, Cohen SE, Gambling D, Palmer C, Huffnagle HJ, Polley L, Muir H, Segal S, Lihou C, Manvelian G. Single-dose, sustained-release epidural morphine in the management of postoperative pain after elective cesarean delivery: results of a multicenter randomized controlled study. Anesth Analg 2005;100:1150–8

48. Carvalho B, Roland LM, Chu LF, Campitelli VA 3rd, Riley ET. Single-dose, extended-release epidural morphine (DepoDur) compared to conventional epidural morphine for post-cesarean pain. Anesth Analg 2007;105:176–83

49. Gambling D, Hughes T, Martin G, Horton W, Manvelian G. A comparison of Depodur, a novel, single-dose extended-release epidural morphine, with standard epidural morphine for pain relief after lower abdominal surgery. Anesth Analg 2005;100:1065–74

50. Viscusi ER, Martin G, Hartrick CT, Singla N, Manvelian G. Forty-eight hours of postoperative pain relief after total hip arthroplasty with a novel, extended-release epidural morphine formulation. Anesthesiology 2005;102:1014–22

51. Hartrick CT, Martin G, Kantor G, Koncelik J, Manvelian G. Evaluation of a single-dose, extended-release epidural morphine formulation for pain after knee arthroplasty. J Bone Joint Surg Am 2006;88:273–81

52. Nagle PC, Gerancher JC. DepoDur:Extended-release epidural morphine: A review of an old drug in a new vehicle. Tech Reg Anesth Pain Manage 2007;11:9–18

53. Greenhalgh CA. Respiratory arrest in a parturient following intrathecal injection of sufentanil and bupivacaine. Anaesthesia 1996;51:173–5

54. Katsiris S, Williams S, Leighton BL, Halpern S. Respiratory arrest following intrathecal injection of sufentanil and bupivacaine in a parturient. Can J Anaesth 1998;45:880–3

55. Ferouz F, Norris MC, Leighton BL. Risk of respiratory arrest after intrathecal sufentanil. Anesth Analg 1997;85:1088–90

56. Lu JK, Manullang TR, Staples MH, Kem SE, Balley PL. Maternal respiratory arrests, severe hypotension, and fetal distress after administration of intrathecal, sufentanil, and bupivacaine after intravenous fentanyl. Anesthesiology 1997;87:170–2

57. Baker MN, Sarna MC. Respiratory arrest after second dose of intrathecal sufentanil. Anesthesiology 1995;83:231–2

58. Hays RL, Palmer CM. Respiratory depression after intrathecal sufentanil during labor. Anesthesiology 1994;81:511–12

59. Jaffee JB, Drease GE, Kelly T, Newman LM. Severe respiratory depression in the obstetric patient after intrathecal meperidine or sufentanil. Int J Obstet Anesth 1997;6:182–4

60. Kuczkowski KM. Respiratory arrest in a parturient following intrathecal administration of fentanyl and bupivacaine as part of a combined spinal-epidural analgesia for labour. Anaesthesia 2002;57:939–40

61. Geller E, Chrubasik J, Graf R, Chrubasik S, Schulte-Monting J. A randomized double-blind comparison of epidural sufentanil versus intravenous sufentanil or epidural fentanyl analgesia after major abdominal surgery. Anesth Analg 1993;76:1243–50

62. Renaud B, Brichant JF, Clergue F, Chauvin M, Levron JC, Viars P. Ventilatory effects of continuous epidural infusion of fentanyl. Anesth Analg 1988;67:971–5

63. Palmer CM, Voulgaropoulos D, Alves D. Subarachnoid fentanyl augments lidocaine spinal anesthesia for cesarean delivery. Reg Anesth 1995;20:389–94

64. Palmer CM. Early respiratory depression following intrathecal fentanyl-morphine combination. Anesthesiology 1991;74:1153–5

65. Madej TH, Strunin L. Comparison of epidural fentanyl with sufentanil. Analgesia and side effects after a single bolus dose during elective caesarean section. Anaesthesia 1987;42:1156–61

66. Arai YC, Ogata J, Fukunaga K, Shimazu A, Fujioka A, Uchida T. The effect of intrathecal fentanyl added to hyperbaric bupivacaine on maternal respiratory function during Cesarean section. Acta Anaesthesiol Scand 2006;50:364–7

67. Brockway MS, Noble DW, Sharwood-Smith GH, McClure JH. Profound respiratory depression after extradural fentanyl. Br J Anaesth 1990;64:243–5

68. Noble DW, Morrison LM, Brockway MS, McClure JH. Adrenaline, fentanyl or adrenaline and fentanyl as adjuncts to bupivacaine for extradural anaesthesia in elective caesarean section. Br J Anaesth 1991;66:645–50

69. Hughes SC. Respiratory depression following intraspinal narcotics: expect it! Int J Obstet Anesth 1997;6:145–6

70. Palmer CM, Emerson S, Volgoropolous D, Alves D. Dose-response relationship of intrathecal morphine for postcesarean analgesia. Anesthesiology 1999;90:437–44

71. Palmer CM, Nogami WM, Van Maren G, Alves DM. Postcesarean epidural morphine: a dose-response study. Anesth Analg 2000;90:887–91

72. Herman NL, Choi KC, Affleck PJ, Calicott R, Brackin R, Singhal A, Andreasen A, Gadalla F, Fong J, Gomillion MC, Hartman JK, Koff HD, Lee SH, Van Decar TK. Analgesia, pruritus, and ventilation exhibit a dose-response relationship in parturients receiving intrathecal fentanyl during labor. Anesth Analg 1999;89:378–83

73. Sia AT, Chong JL, Chiu JW. Combination of intrathecal sufentanil 10 mug plus bupivacaine 2.5 mg for labor analgesia: is half the dose enough? Anesth Analg 1999;88:362–6

74. Albright GA, Forster RM. The safety and efficacy of combined spinal and epidural analgesia/anesthesia (6,002 blocks) in a community hospital. Reg Anesth Pain Med 1999;24:117–25

75. Norris MC, Fogel ST, Holtmann B. Intrathecal sufentanil (5 vs. 10 microg) for labor analgesia: efficacy and side effects. Reg Anesth Pain Med 1998;23:252–7

76. Fournier R, Gamulin Z, Van Gessel E. Respiratory depression after 5 micrograms of intrathecal sufentanil. Anesth Analg 1998;87:1377–8

77. Richardson MG, Wissler RN. Densities of dextrose-free intrathecal local anesthetics, opioids, and combinations measured at 37 degrees C. Anesth Analg 1997;84:95–9

78. Hamilton CL, Cohen SE. High sensory block after intrathecal sufentanil for labor analgesia. Anesthesiology 1995;83:1118–21

79. Rofaeel A, Lilker S, Fallah S, Goldszmidt E, Carvalho J. Intrathecal plain vs hyperbaric bupivacaine for labour analgesia: efficacy and side effects. Can J Anaesth 2007;54:15–20

80. Etches RC, Sandler AN, Daley MD. Respiratory depression and spinal opioids. Can J Anaesth 1989;36:165–85

81. Bailey PL, Rhondeau S, Schafer PG, Lu JK, Timmins BS, Foster W, Pace NL, Stanley TH. Dose-response pharmacology of intrathecal morphine in human volunteers. Anesthesiology 1993;79:49–59; discussion 25A

82. Brose WG, Cohen SE. Oxyhemoglobin saturation following cesarean section in patients receiving epidural morphine, PCA, or im meperidine analgesia. Anesthesiology 1989;70:948–53

83. Keck S, Glennon C, Ginsberg B. DepoDur extended-release epidural morphine: reshaping postoperative care. What perioperative nurses need to know. Orthop Nurs 26:86–93, 2007; quiz 4–5

84. Celleno D, Capogna G, Sebastiani M, Costantino P, Muratori F, Cipriani G, Emanuelli M. Epidural analgesia during and after cesarean delivery. Comparison of five opioids. Reg Anesth 1991;16:79–83

85. Ready LB, Loper KA, Nessly M, Wild L. Postoperative epidural morphine is safe on surgical wards. Anesthesiology 1991;75:452–6

86. Abboud TK, Moore M, Zhu J, Murakawa K, Minehart M, Longhitano M, Terrasi J, Klepper ID, Choi Y, Kimball S, et al. Epidural butorphanol or morphine for the relief of post-cesarean section pain: ventilatory responses to carbon dioxide. Anesth Analg 1987;66:887–93

87. Sun HL. Naloxone-precipitated acute opioid withdrawal syndrome after epidural morphine. Anesth Analg 1998;86:544–5

88. Johnson A, Bengtsson M, Soderlind K, Lofstrom JB. Influence of intrathecal morphine and naloxone intervention on postoperative ventilatory regulation in elderly patients. Acta Anaesthesiol Scand 1992;36:436–44

89. Thind GS, Wells JC, Wilkes RG. The effects of continuous intravenous naloxone on epidural morphine analgesia. Anaesthesia 1986;41:582–5

90. Cannesson M, Nargues N, Bryssine B, Debon R, Boselli E, Chassard D. Intrathecal morphine overdose during combined spinal-epidural block for Caesarean delivery. Br J Anaesth 2002;89:925–7

Cited By:

This article has been cited 3 time(s).

Annales Francaises D Anesthesie Et De Reanimation
Hypothermia after intrathecal morphine for caesarean delivery: Another case report
Harkouk, H; de Preville, G; Benhamou, D
Annales Francaises D Anesthesie Et De Reanimation, 32(1): 53-55.
10.1016/j.annfar.2012.10.013
CrossRef
Pain Research & Management
Life-threatening adverse events following therapeutic opioid administration in adults: Is pharmacogenetic analysis useful?
Madadi, P; Sistonen, J; Silverman, G; Gladdy, R; Ross, CJ; Carleton, BC; Carvalho, JC; Hayden, MR; Koren, G
Pain Research & Management, 18(3): 133-136.

International Journal of Obstetric Anesthesia
Transcutaneous carbon dioxide levels and oxygen saturation following caesarean section performed under spinal anaesthesia with intrathecal opioids
Dalchow, S; Lubeigt, O; Peters, G; Harvey, A; Duggan, T; Binning, A
International Journal of Obstetric Anesthesia, 22(3): 217-222.
10.1016/j.ijoa.2013.04.003
CrossRef
Back to Top | Article Outline

© 2008 International Anesthesia Research Society

Login

Become a Society Member